

Dose-Dependent Effects of Focal Fractionated Irradiation on Secondary Malignant Neoplasms in *Nf1* Mutant Mice

Jean L. Nakamura¹, Connie Phong¹, Emile Pinarbasi¹, Scott C. Kogan², Scott Vandenberg³, Andrew E. Horvai², Bruce A. Faddegon¹, Dorothea Fiedler⁴, Kevan Shokat⁴, Benjamin T. Houseman⁴, Richard Chao⁵, Russell O. Pieper⁶, and Kevin Shannon⁷

Abstract

Secondary malignant neoplasms (SMN) are increasingly common complications of cancer therapy that have proven difficult to model in mice. Clinical observations suggest that the development of SMN correlates with radiation dose; however, this relationship has not been investigated systematically. We developed a novel procedure for administering fractionated cranial irradiation (CI) and investigated the incidence and spectrum of cancer in control and heterozygous *Nf1* mutant mice irradiated to a moderate (15 Gy) or high dose (30 Gy). Heterozygous *Nf1* inactivation cooperated with CI to induce solid tumors and myeloid malignancies, with mice developing many of the most common SMNs found in human patients. CI-induced malignancies segregated according to radiation dose as *Nf1*^{+/-} mice developed predominately hematologic abnormalities after 15 Gy, whereas solid tumors predominated at 30 Gy, suggesting that radiation dose thresholds exist for hematologic and nonhematologic cancers. Genetic and biochemical studies revealed discrete patterns of somatic *Nf1* and *Trp53* inactivation and we observed hyperactive Ras signaling in many radiation-induced solid tumors. This technique for administering focal fractionated irradiation will facilitate mechanistic and translational studies of SMNs. *Cancer Res*; 71(1); 106–115. ©2011 AACR.

Introduction

Secondary malignant neoplasms (SMN) are late complications arising after exposure to genotoxic therapies, which include radiotherapy and many chemotherapeutic agents. SMNs account for most of the approximately 90,000 new cancers that are diagnosed annually in the United States in persons who previously had a histologically distinct malignancy (1). Moreover, the incidence of SMNs is expected to grow as the at-risk population of cancer survivors treated with intensive therapeutic regimens increases. This prediction is consistent with data showing that the dramatic improvement in the cure rates of many pediatric cancers over the past few decades was followed by increasing numbers of SMNs (2). SMNs are often high-grade, aggressive tumors that are resis-

tant to therapy. Because the mechanisms underlying SMN development are poorly understood and experimental models are lacking, fundamental questions about SMN pathogenesis and treatment have not been addressed.

Nearly two thirds of cancer patients receive radiotherapy. Modern treatment protocols typically involve administering a high dose of fractionated irradiation to a defined anatomic site of disease. Retrospective studies have shown that the vast majority of SMNs arise in tissues that were included in the radiation field and support a relationship between the total dose of radiation and tumorigenesis (3). Murine studies of radiation mutagenesis have generally employed single, low-dose total body irradiation (TBI), which does not accurately model the high-dose targeted radiotherapy most cancer patients receive. Furthermore, existing mouse models have not specifically addressed the relationship of treatment parameters such as focal radiation dose to the subsequent risk and spectrum of SMNs. Although unexamined, this relationship is important clinically because contemporary radiotherapy techniques are capable of delivering extremely conformal radiation dose distributions and differentially dosing multiple malignant and normal structures.

Mutations in the *NF1* tumor suppressor gene cause neurofibromatosis type 1 (NF1), a common familial cancer syndrome (4, 5). *NF1* encodes neurofibromin, a GTPase-activating protein (GAP) that negatively regulates Ras signaling (6, 7). Affected individuals are predisposed to specific benign and malignant tumors, which include tumors of the central and peripheral nervous systems, soft tissue sarcomas, pheochromocytoma, and juvenile myelomonocytic leukemia

Authors' Affiliations: Departments of ¹Radiation Oncology and ²Laboratory Medicine, University of California, San Francisco, California; ³Department of Pathology, University of California, San Diego, California; ⁴Department of Cellular and Molecular Pharmacology, University of California, San Francisco, California; ⁵Pfizer Global Research and Development, San Diego, California; and Departments of ⁶Neurological Surgery and ⁷Pediatrics, University of California, San Francisco, California

Note: Supplementary data for this article are available at Cancer Research Online (<http://cancerres.aacrjournals.org/>).

Corresponding Author: Jean L. Nakamura, Department of Radiation Oncology, University of California, Helen Diller Family Cancer Research Building, 1450 Third Street, Room 231, San Francisco, CA 94158. Phone: 415-353-9694; Fax: 415-353-8679. E-mail: jnakamura@radonc.ucsf.edu

doi: 10.1158/0008-5472.CAN-10-2732

©2011 American Association for Cancer Research.

(JMML; ref. 8). In addition, retrospective clinical data suggest that persons with NF1 who are treated with genotoxins for a primary cancer are at increased risk of developing common SMNs such as myeloid leukemia, soft tissue sarcomas, and malignant gliomas (9, 10).

We previously found that TBI, when delivered alone or in combination with cyclophosphamide, induced a spectrum of SMNs in *Nf1*^{+/-} mice that include myeloid malignancies, soft tissue sarcomas, and breast carcinomas. Because low-dose TBI does not accurately model current radiation oncology practice for the majority of patients, we developed a customized technique to model clinical brain radiotherapy by delivering focal, fractionated cranial irradiation (CI) to mice.

Here we show that CI cooperates with heterozygous *Nf1* inactivation to induce solid tumors and hematologic malignancies. Importantly, we observed a clear threshold for disease induction with almost all of myeloid malignancies occurring in mice that received 15 Gy, whereas solid tumors concentrated in the cohort that received 30 Gy. Some types of radiation-induced tumors consistently showed somatic loss of the normal *Nf1* alleles whereas others did not, which suggests that Ras-dependent and -independent mechanisms contribute to radiation-induced tumorigenesis. Consistent with this idea, we obtained evidence for hyperactive Ras signaling in primary radiation-induced tumors from both wild-type (WT) and *Nf1* mutant mice. Together, these studies establish a new approach for modeling clinical radiation therapy regimens in mice, reveal cooperation between *Nf1* inactivation and focal CI in generating SMNs, and identify hyperactive Ras as a potential biochemical target in common SMNs.

Materials and Methods

Mouse strains, breeding, and treatment

Nf1^{+/-} mice were generated as previously described (11). In brief, *Nf1*^{+/-} mice maintained in the 129/Sv background (12) were crossed with WT C57Bl/6 mice. We modified a previously published rat brain irradiation protocol developed at our institution to reproducibly irradiate murine brains *in vivo* (13). Mice were placed 16.3 cm from a cesium-137 source (J.L. Shepherd & Associates) and shielded with an iron collimator that limited the beam width to a narrow 1 centimeter wide vertical beam. Mice (6- to 8-weeks old) were given CI at a fractionation of either 5 fractions of 3 Gy or 10 fractions of 3 Gy, delivered at a rate of 5 fractions per week, 1 fraction per day. All animal procedures were approved by the UCSF IACUC.

Pathologic analysis

Animals with signs of systemic illness were euthanized and visible masses/growths, peripheral blood, and bone marrow were collected immediately. The mice were then perfused with 4% paraformaldehyde and the following organs were collected: brain, skin in irradiated region, skin outside irradiated region, skull, heart, lungs, spleen, liver, kidneys, and segment of small intestine. Pathologic review was done on hematoxylin and eosin-stained sections by A.H., S.K., or S.V. Complete blood

counts (CBC) were done on blood samples obtained at the time of sacrifice by cardiac puncture and analyzed immediately on a Hemavet provided by the UCSF Mouse Pathology Core.

Immunohistochemistry

Five-micrometer sections were obtained through paraffin-embedded tumors. Phosphorylated ERK Thr202/Tyr204 (catalog #4376), phosphorylated Akt Ser473 (#9271) and phosphorylated S6 Ser235/236 (#2211; all from Cell Signaling) were assessed on paraffin-embedded sections using immunofluorescent staining as described previously (14). Slides were visualized on a fluorescent microscope and 6 independent fields were scored for relative fluorescence at $\times 40$ magnification by a blinded reviewer (J.N.). These scores were then averaged to generate the fluorescence score. Images were captured and merged using Openlab (Improvision).

Genotyping and mutation analysis

Trp53 loss of heterozygosity was analyzed at the D11Mit29 and D11Mit31 loci by amplifying tumor DNA with the following primers: forward 5'-TTGAGGCATGAGGGGATTAG-3', reverse 5'-TTTCCGTCATTGCTAAAGGG-3', 5'-TTTCCCAGTCACGACGTTGGCCTGAATTCACATGTTGG-3', reverse 5'-AGAATAAGTAAACCCAGCTGCG-3'. D11Mit219 was amplified with the following primers: forward 5'-TTTCCCAGTCACGACGTTGTTGTATGTATAGATGCATTTGAATGG 3', reverse 5'-GGTTTGATAAATTCTCACCTGTGC-3'. PCR fragment analyses were done by the UCSF Genome Core using Peak Scanner software from Applied Biosystems. SNP rs13481119 was amplified using the following primers: forward GC CCGCTACATG CTGATGCTG reverse GCTTGTAGGCCTGGT-GAGTC. SNP products were sequenced using a commercial sequencing service.

Cell culture

Nf1^{-/-}, *Nf1*^{+/-}, and WT mouse embryo fibroblasts were generated as previously described (15). Tumor cell lines were generated as previously described (11). All cell lines were grown in Dulbecco's modified Eagle medium (4,500 mg/L glucose; Life Technologies, Inc.) supplemented with 10% fetal bovine serum (GIBCO-BRL, Invitrogen), penicillin, and streptomycin. Cells were grown in a humidified incubator containing 5% carbon dioxide at 37°C.

Quantitation of γ H2AX foci formation

Cells grown on glass coverslips were irradiated, then fixed with 4% paraformaldehyde at specified time points. Coverslips were permeabilized and probed with anti- γ H2AX Ser139 antibody (Millipore), followed by anti-rabbit AlexaFluor 488 secondary antibody (Molecular Probes). Coverslips were mounted using Vectashield with 4',6 diamidino 2 phenylindole (DAPI; Vector Laboratories), and visualized with a Zeiss LSM 510 Meta confocal microscope.

Statistical analysis

Survival curves are calculated from Kaplan-Meier product limit estimators to determine the association of CI on

mortality. Interim sacrifices of moribund animals are taken as uncensored events whereas the terminal, end-of-study sacrifices are necessarily considered censored. Log-rank tests are used to test for differences in survival curves between groups. Fisher–Irwin exact tests are used to make pairwise comparisons of total disease incidence between dosage groups. Cochran–Armitage tests for trend are used to consider all dosage groups together. Disease-specific incidence is compared using both unadjusted and survival-adjusted analyses. Two-way ANOVAs were used to assess the effects of genotype and radiation dosage on hemoglobin levels, white blood cell count, and platelet count. Two-tailed *t* tests were used to make pairwise comparisons of hemoglobin levels, white blood cell counts, and platelet counts. All analyses were done on R 2.7.0.

Results

Survival and tumorigenesis after CI

CI is one of the most common types of radiation therapy, and a significant fraction of SMNs observed today result from prior brain irradiation. To replicate this treatment experimentally, we developed customized beam shaping to deliver focal, fractionated, CI to mice (Supplementary Fig. S1A). Similar to the whole brain irradiation technique used in patients, equally weighted, opposed lateral beams were used to deliver multi-fraction CI to mice. Radiographic film was used to quantitate radiation dosimetry, describing the absolute radiation dose rate both within and outside the irradiation field, and the dose homogeneity across the beam aperture (Supplementary Fig. S1B).

The study cohort included 121 mice that were generated by mating *Nf1*^{+/-} mice on a 129/Sv strain background and WT C57Bl/6 mice. These F1 *Nf1*^{+/-} (*n* = 73) and WT (*n* = 48) mice were assigned to 1 of the following 3 CI treatment regimens: 0 Gy, 15 Gy (5 doses of 3 Gy), or 30 Gy (10 doses of 3 Gy). Fraction sizes were maintained at 3 Gy to determine the effect of total radiation dose on disease development. These radiation doses were selected to approximate clinically used radiation fractionation schemes, and mice were irradiated 5 times per week, 1 fraction per day, identical to clinical practice. Mice were observed for 18 months after radiation treatment or until they developed signs of systemic illness that necessitated euthanasia.

As expected from previous reports (11, 12, 16), the survival of unirradiated *Nf1*^{+/-} mice was reduced compared to WT littermates (*P* = 0.02, log-rank test) with deaths occurring after 1 year of age (Fig. 1A). CI significantly decreased the survival of both WT (*P* = 0.002, log-rank test) and *Nf1*^{+/-} (*P* = 0.05, log-rank test) mice (Fig. 1A). Furthermore, there were increased risks of death in *Nf1*^{+/-} versus WT mice with a hazard ratio of death of 2.041 (95% CI: 1.116–3.735) and in irradiated mice over unirradiated mice with a hazard ratio of death of 3.788 (95% CI: 1.618–8.870). The median posttreatment survival time was reduced in irradiated *Nf1*^{+/-} mice compared with irradiated WT mice (503 versus 596 days; *P* = 0.04, log-rank test), showing that the worst overall outcome was observed in irradiated *Nf1*^{+/-} mice. Interestingly, the survival of both WT and *Nf1*^{+/-} mice was reduced to a similar




Figure 1. Overall survival and disease-specific survival after CI. Kaplan–Meier survival curves were used to depict overall survival, solid tumor-free survival, and hematologic disease-free survival in WT and *Nf1* mutant mice. Log-rank tests were used to test for differences between survival curves. The latency to death was measured from the date of the last radiation fraction. A and B, WT and *Nf1* mutant mice had decreased survival after CI. C and D, Kaplan–Meier cause-specific survival curves were generated to reflect death due to hematologic malignancies or solid tumors. *Nf1*^{+/-} mice exposed to 15 Gy CI were significantly more likely to die with hematologic disease than those that were unirradiated or exposed to 30 Gy CI (HR 4.151, 95% CI: 0.9081–18.971, *P* = 0.0465). D, *Nf1*^{+/-} mice exposed to 30 Gy CI were significantly more likely to die of solid tumors than mice that were unirradiated or exposed to 15 Gy CI (HR 1.659, 95% confidence interval: 0.3037 – 9.058, *P* = 0.04).

extent by either moderate-dose (3 Gy × 5) or high-dose (3 Gy × 10) CI (Fig. 1B).

Nf1^{+/-} mice develop radiation-induced cancers in a dose-related manner

Pathologic analyses were done on 120 of 121 mice in the study cohort, including 116 that had histopathologic evaluation of cranial and hematologic organs. A few early deaths in WT and *Nf1* mutant mice were consistent with radiation-induced cerebral edema, a known side effect of CI. Necropsies of both moribund and terminally sacrificed mice revealed the predominance of 2 distinct disease phenotypes: solid tumor in

the irradiated region (in-field tumors) and myeloid malignancies. The latency before the onset of clinical signs that necessitated euthanasia was similar in mice that died with solid tumors and myeloid malignancies. Early stage solid tumors and myeloid malignancies were evident at necropsy in some asymptomatic mice, and were more common in irradiated *Nf1* mutant than in irradiated WT controls ($P = 0.003$, log-rank test). Overall, irradiated *Nf1* mutant mice were more likely than irradiated WT mice to develop hematologic malignancies ($P = 0.003$, log-rank test) or solid cancers ($P = 0.05$). Analysis of overall tumor incidence confirmed a positive, linear association with radiation dose ($P = 0.0395$, survival adjusted Cochran–Armitage trend test) and the tumorigenicity of the 30-Gy dose over 15-Gy dose ($P = 0.04$, Fisher exact test). We performed log-rank tests to compare disease-specific survival and observed the highest incidence of myeloid malignancies in *Nf1* mutant mice that received 15 Gy of CI (Fig. 1C; 0 Gy versus 15 Gy: $P = 0.031$, 15 Gy versus 30 Gy: $P = 0.017$, Fisher exact tests). By contrast, disease-specific survival due to solid tumor was significantly reduced in *Nf1* mutant mice receiving 30 Gy of CI ($P = 0.019$, log-rank test; Fig. 1D). Thus, whereas exposure to 15 Gy of focal radiation was more leukemogenic than 30 Gy, the incidence of solid cancers was greater at the higher radiation dose. CI did not reach significance with regard to altered disease-specific survivals due to solid tumor or hematologic malignancy in WT mice.

Radiation-induced solid tumors after CI

Mice receiving CI developed several types of solid tumors arising from the central nervous system, bone, skin and orbits within the irradiated region. These in-field solid tumors included squamous cell carcinomas, osteosarcoma, malignant peripheral nerve sheath tumor, papillary carcinoma, pituitary adenomas, choroid plexus papilloma, and lymphomas, which arose within the irradiated field and were classified as solid cancers in our analyses (Fig. 2; Supplementary




Figure 2. Solid cancers arising after high-dose focal CI. Five micrometer paraformaldehyde-fixed, paraffin-embedded tumor sections were stained with hematoxylin and eosin and histologically classified. A, papillary carcinoma; B, squamous cell carcinoma; C, pituitary adenoma; D, malignant peripheral nerve sheath tumor. Bars = 50 μ m.

Table S1). The latencies associated with these tumors were roughly similar, with the majority developing at least 1 year after CI.

Myeloid malignancies after CI

Nf1^{+/-} mice developed a spectrum of myeloid disorders, which occurred in animals that succumbed prematurely and incidentally in animals that were analyzed at the end of the experiment. Early death was most common in *Nf1*^{+/-} mice that received 15 Gy of CI (Fig. 1C). Pathologic analysis of most of these mice revealed a disorder that was reminiscent of human myelodysplastic syndrome (MDS), which is characterized by ineffective hematopoiesis and anemia. We obtained CBC from 96 of 121 (80%) mice in the study cohort at death from disease or elective euthanasia and found that anemia was largely restricted to *Nf1*^{+/-} mice that received 15 Gy of CI (Fig. 3A). There were no significant differences in blood leukocyte or platelet counts segregating with either genotype or radiation dosage. Because anemia occurs in some human patients with advanced solid cancers, we compared the CBCs of mice that developed solid tumors to those of mice without solid tumors. All parameters, including hemoglobin levels, were comparable between mice that were euthanized due to a solid tumor and mice without overt disease (Fig. 3B). In comparison with normal mice (Fig. 3C, top row), most *Nf1*^{+/-} mice that received 15 Gy of CI showed marked expansion of the red pulp in the spleen (Fig. 3C, left and middle, middle row), which was characterized by a predominance of erythroid cells, and bone marrows that contained a mix of myeloid and erythroid elements (Fig. 3C, right, middle row). The presence of marked splenic erythroid hyperplasia along with persistent erythropoiesis in the bone marrow and peripheral anemia strongly suggests ineffective hematopoiesis: a finding that parallels the abnormal erythroid development seen in human refractory anemia and related MDS. In humans, MDS following irradiation may also be hypoplastic, in contrast to the hypercellular marrows more typical of MDS. Interestingly, some mice in the *Nf1*^{+/-} 15-Gy cohort with marked peripheral anemia showed minimal splenic red pulp expansion (Fig. 3C, left, last row) with erythroid precursors present, but not expanded in the spleen (Fig. 3C, middle, last row) and bone marrow (Fig. 3C, right, last row). Although the cause of the hypoplastic anemias observed in these mice is not certain, we speculate that these animals developed an illness paralleling human hypoplastic MDS.

Pathologic analysis of *Nf1*^{+/-} mice also identified some with hematologic abnormalities that were distinct from the MDS-like phenotypes seen in the 15-Gy cohort. *Nf1*^{+/-} mice are predisposed to spontaneously develop a myeloproliferative neoplasm in the second year of life that models human JMML and is characterized by leukocytosis and splenomegaly without anemia (12, 16). Consistent with this, spleen weight averaged 0.588 grams in *Nf1*^{+/-} mice and 0.200 grams in WT mice, and was independent of radiation dose. We also observed 4 cases of histiocytic sarcoma in *Nf1*^{+/-} mice, 2 of which were detected incidentally after elective euthanasia.




Figure 3. Hematologic malignancies observed after high-dose focal CI. Five micrometer paraformaldehyde-fixed, paraffin-embedded sections of spleen and sternum were stained with hematoxylin and eosin. A, box plots of hemoglobin levels at the time of sacrifice for each treatment group. *Nf1* mutant mice exposed to 15 Gy CI are significantly more anemic compared with *Nf1* mutant mice that are unirradiated or exposed to 30 Gy CI, and compared to all WT mice ($P < 0.05$, 2-tailed test). Thick black line indicates median, upper edge of box indicates third quartile, lower edge of box indicates first quartile. B, box plots of hemoglobin levels were compared on the basis of cause of death. Mice sacrificed due to hematologic disease were anemic compared to those who did not have histologic evidence of hematologic disease ($P < 0.001$, 2-tailed test), although no significant difference in hemoglobin levels was observed between mice that did and did not die of solid tumor. C, top row, left to right, normal spleen (20 \times and 100 \times), and bone marrow (100 \times) from an unirradiated *Nf1* mutant mouse. Middle row, left to right: spleen (20 \times and 100 \times) and bone marrow (100 \times) from an irradiated *Nf1* mutant mouse with peripheral anemia. Bottom row, left to right, spleen (20 \times and 100 \times) and bone marrow (100 \times) from an irradiated *Nf1* mutant mouse that developed anemia but whose spleen and marrow lacked erythropoietic expansion.

Genetic alterations in radiation-induced tumors

The F1 background of our study cohort allowed us to use strain-specific polymorphisms to screen tumors for loss of constitutional heterozygosity (LOH). Because the *Nf1* mutant allele was maintained on the 129/Sv background, loss of the *Nf1* allele derived from the C57Bl/6 parent results in homozygous inactivation. *Trp53*, the murine homologue of the tumor suppressor *Tp53* in humans, is separated from the *Nf1* gene by 9.7 Mb on mouse chromosome 11, and concurrent loss of *Nf1* and *Trp53* genes accelerates tumorigenesis in mice (17, 18). We used a PCR-based technique that employs fluorescently-labeled probes amplifying DNA fragments corresponding to microsatellite sequence polymorphisms to analyze 6 primary solid tumors from *Nf1*^{+/-} mice for LOH at *Nf1* and *Trp53*. The loci examined included 3 microsatellite markers: D11Mit29, which is closely linked to *Trp53*; D11Mit31 and D11Mit219, which are located between *Trp53* and *Nf1*; and

rs13481119, an intragenic *Nf1* single nucleotide polymorphism (Fig. 4A). These studies revealed marked reduction in the C57Bl/6-derived allele at all 4 loci in a CI-induced sarcoma (Fig. 4B–D). By contrast, 2 of 4 squamous cell carcinomas showed LOH at *Nf1*, but all of these tumors retained both *Trp53* alleles (Fig. 4C–D). A pituitary adenoma was the only tumor displaying loss of the 129/Sv-derived *Nf1* allele at all 4 loci examined, which infers that *Nf1* loss does not drive tumorigenesis in this context. In contrast to the solid tumors, *Nf1* inactivation was uncommon in radiation-induced myeloid malignancies with only 2 of 12 splenic DNA samples showing LOH at *Nf1*.

We also used this sensitive platform to analyze 12 malignant solid tumors that developed in *Nf1*^{+/-} mice after TBI that have been reported by Chao et al. (11). These studies confirmed a high frequency of LOH at the *Nf1* locus in sarcomas (6 of 8) and mammary tumors (4 of 4), and LOH at *Trp53* in all of




Figure 4. Molecular analysis at the *Trp53* and *Nf1* loci. A, schematic of mouse chromosome 11 depicting the positions of the microsatellite markers and SNP assessed relative to *Trp53* and *Nf1*. Microsatellite markers D11Mit29, D11Mit31, and D11Mit219 were used to assess *Trp53* and the intervening region between *Trp53* and *Nf1* in radiation-induced tumors and normal tail controls. B, fragment analysis of the D11Mit29 locus reveals that normal tissue from C57Bl/6 (B6) and 129/Sv (129) mice show discrete peaks at 141 and 147/149, respectively, and these allelic contributions are readily visualized in F1 mice. In radiation-induced osteosarcoma tumor (OS, an osteosarcoma arising in a *Nf1* mutant mouse receiving 30 Gy C) DNA the B6 fragment is significantly reduced (*) compared to control tail DNA. C, SNP rs13481119 was sequenced, showing heterozygosity in F1 mice. Comparison of tumor DNA to matched tail shows intact heterozygosity in SCCA (a squamous cell carcinoma), reduction of B6 peak in OS, and reduction of 129 peak in a pituitary adenoma. D, the pattern of LOH is described for each microsatellite and SNP locus by tumor type arising in *Nf1* mutant mice. The number of tumors losing the C57Bl/6 allele (table on left) or 129/Sv allele (table on right) is listed over the total number of tumors assessed at the locus.

the mammary tumors (Supplementary Table S2). Sufficient DNA was available from 5 TBI-induced sarcomas for genotyping at all 4 loci, and revealed LOH extending to *Trp53* in 2 of these tumors that was not detected previously (11).

Ras signaling is activated in radiation-induced tumors

Nf1 loss results in hyperactive Ras signaling and activation of canonical downstream kinase effector cascades in many cell types. To investigate Ras pathways implicated in cancer, we performed immunohistochemical analysis of primary radiation-induced tumors with antibodies that recognize phosphorylated forms of ERK, Akt and S6 (pERK, pAkt, and pS6) and devised a semiquantitative scoring system to compare staining intensity with a score of "1" corresponding to no detectable phospho-protein and a score of "3" reflecting diffuse and uniform staining. We observed elevated pAkt and pS6 levels in most tumors compared with normal tissues with considerable variability between individual tumors (Fig. 5). Whereas some tumors displayed good concordance between

pAkt and pS6 levels, several tumors showed proportionately more pS6 staining (Fig. 5A), and pS6 was most consistently elevated *in vivo* relative to normal tissues in radiation-induced tumors (Fig. 5B). By contrast, we detected elevated levels of pERK less frequently in primary tumors compared to pAkt and pS6 (Supplementary Fig. S2). The ranges of pAkt and pS6 levels were similar in radiation-induced tumors from WT and *Nf1*^{+/-} mice, and loss of the normal *Nf1* allele did not have consistent effects on pERK, pAkt, or pS6 levels (Fig. 5A; Supplementary Fig. S2).

Radiation response in WT and *Nf1* mutant cells

The mechanisms underlying the sensitivity of individuals with NF1 and *Nf1* mutant mice to radiation-induced tumors are unknown. Defects in DNA repair underlie some disorders that result in cancer susceptibility after radiation exposure, such as ataxia-telangiectasia (19). Although neurofibromin possesses a nuclear localization signal, it has no known role in maintaining genomic integrity (20). To determine whether




Figure 5. *In vivo* analysis of Ras effector phosphorylation in tumor tissues. Five micrometer tumor sections were stained with DAPI and phospho-specific antibodies were used to visualize *in vivo* levels of pS6 and pAkt. A, tumor sections were visualized with fluorescence microscopy and six 40× fields from each section were scored in blinded fashion as either 1 (no signal), 2 (low signal) or 3 (high signal), then averaged. Average scores for pS6 and pAkt are plotted. Tumors in which LOH at SNP rs13481119 (intragenic to *Nf1*) were assessed are indicated as follows: tumors showing intact heterozygosity at SNP rs13481119 are plotted as light blue circles, with LOH of B6 allele as dark blue squares, or with LOH of 129 allele as magenta squares. B, phosphorylated S6 (pS6) levels are elevated in tumor sections from a radiation-induced pituitary adenoma and osteosarcoma, whereas pAkt levels are not correspondingly elevated. Bar = 50 μm.

Downloaded from <http://aacrjournals.org/cancerres/article-pdf/71/1/106/2652376/106.pdf> by guest on 10 August 2022

heterozygous or homozygous *Nf1* inactivation might subtly alter this response, we compared γ H2AX formation in WT, $Nf1^{+/-}$ and homozygous *Nf1* mutant ($Nf1^{-/-}$) MEFs that were exposed to low-dose irradiation (Supplementary Fig. S3). H2AX is a histone protein phosphorylated by ATM in response to the presence of double strand DNA breaks, resulting in the

formation of nuclear γ H2AX foci (19). Resolution of these foci over time reflects DNA repair capacity. We observed similar patterns of γ H2AX foci formation and resolution over time in WT and *Nf1* mutant mouse embryo fibroblasts, which suggests that *Nf1* inactivation does not have global effects on DNA repair.

Discussion

The risk of late toxicities after cancer therapy concerns virtually every cancer survivor, and SMNs are the most severe and life-threatening of these complications. Indeed, the ongoing experience of childhood cancer survivors who were cured with intensive genotoxic regimens suggests that the development of SMNs might ultimately compromise recent improvements in cancer survival (1, 21, 22). Although common, SMNs have proven difficult to study clinically and experimentally. Patients with NF1 are predisposed to many of the same SMNs as the general population (10) and *Nf1*^{+/-} mice are a genetically sensitized background for investigating tumorigenesis secondary to radiation and/or chemotherapeutic agents (11, 16). However, "first generation" models do not recapitulate current clinical practice in which high-dose fractionated radiotherapy is administered to a defined anatomic site of disease. We have overcome this limitation by developing a technique for delivering localized multidose CI to mice. Furthermore, individuals with NF1 are predisposed to specific CNS tumors and the risk of subsequent SMN induction influences their care (10). We found that solid tumor development was dose-related and occurred within the radiation field, mirroring clinical observations in childhood cancer survivors (23). The long latencies and diverse histologies of these squamous cell carcinomas, osteosarcomas, and soft tissue sarcomas also reflect the natural history of SMNs. Importantly, *Nf1*^{+/-} and *Nf1*^{-/-} MEFs activate the p53 pathway in response to doxorubicin (11) and we observed normal γ H2AX foci formation and resolution after irradiation. Together, these clinical, pathologic, and biologic characteristics suggest that administering high-dose focal irradiation to *Nf1* mutant mice is a robust system for accurately modeling common SMNs in the general population that has some advantages over using *Atm* or *Trp53* mutant mice, which show abnormal responses to DNA damage.

We did not observe radiation-induced gliomas or meningiomas in *Nf1*^{+/-} mice that were exposed to CI. This was unexpected as both are well-recognized SMNs after CI (10, 24, 25) and mice that inherit mutations in *Nf1* and *Trp53* in *cis* are predisposed to malignant gliomas (17, 26, 27). Our data therefore suggest that loss of *Trp53* may be an early and rate-limiting event in gliomagenesis. Alternatively, the latency to glioma development may exceed that of other solid tumor types, and euthanizing mice due to non-gliomatous disease precluded the detection of radiation-induced gliomas.

Nf1^{+/-} mice that were treated with focal CI died with a hematologic disorder that was highly reminiscent of human MDS, and it is provocative that these malignancies arose predominantly at the lower radiation dose level. Our data showing an upper radiation dose threshold defining risk are consistent with clinical observations that hematologic cancers are extremely rare with high-dose focal irradiation, but can be induced by low-dose focal irradiation in individuals receiving radiotherapy for benign illnesses (28). The mechanisms by which low to moderate-dose irradiation induces hematologic malignancies are unknown. Importantly, however, injury to the entire hematopoietic stem cell compartment cannot

account for the occurrence of MDS and other hematologic disorders in our model as the focal CI protocol spared most of the blood-forming marrow. However, in contrast to humans, the murine cranium possesses blood-forming capacity. Instead, our data argue strongly in favor of a mechanism in which radiation induces genetic damage in a susceptible cell, which subsequently achieves clonal dominance. We speculate that exposure to high-dose radiation ablates most potential leukemia-initiating cells whereas lower doses induce sublethal genetic damage that promotes clonal outgrowth and ultimately results in frank hematologic malignancy.

In addition to total radiation dose, fraction size could influence the dose dependence of radiation-induced tumorigenesis in our model. In certain clinical situations, increasing fractionation of radiotherapy, which increases the number of radiation exposures but decreases the dose per exposure, is favored over single exposure radiotherapy to favor normal tissue repair that can occur between fractions. One might then expect that increasing fractionation would be associated with fewer SMNs. Alternatively, it is possible that multifraction radiotherapy, possibly in settings in which DNA repair in normal tissues is compromised, may increase the risk of SMN development due to the successive accumulation of mutations over the course of radiotherapy. We did not address the issue of fraction size in this study and these mechanisms are worth further study.

Molecular analysis at the *Nf1* and *Trp53* loci revealed 3 general patterns of genetic alterations in tumors from mice that received either high-dose focal CI or low-dose TBI: LOH involving *Nf1* only; LOH at *Nf1*, *Trp53*, and 2 intervening loci; and intact heterozygosity. Consistent with the increased risk of cancer in irradiated *Nf1*^{+/-} mice, *Nf1* is affected by LOH more commonly than *Trp53*. *Nf1* inactivation is highly prevalent in mammary tumors and sarcomas from mice that received low-dose TBI (11), and was also observed in a sarcoma that arose after high-dose focal CI. By contrast, LOH at *Nf1* was less common in mice that developed squamous cell carcinoma after high-dose focal CI, and was surprisingly infrequent in myeloid malignancies that emerged in *Nf1*^{+/-} mice treated with either radiation regimen (11). It is possible that radiation-induced *Nf1* inactivation in leukemia-initiating cells is due to mechanisms that do not result in LOH such as small intragenic deletions or point mutations in the normal *Nf1* allele. Alternatively, haploinsufficiency for *Nf1* might cooperate with radiation-induced mutations of other genes in myeloid leukemogenesis. Interestingly, the low incidence of LOH at *Nf1* in mice with radiation-induced myeloid malignancies is consistent with data from human NF1 patients who developed secondary leukemia (9).

Immunohistochemical analysis revealed elevated levels of pAkt and pS6 in many radiation-induced tumors, which did not correlate with either the *Nf1* mutant genotype or with somatic loss of the normal *Nf1* allele. The variable levels of pAkt, pS6, and pERK that we observed in tumor from *Nf1*^{+/-} mice infer that Ras signaling is modulated during the complex process of multistep tumorigenesis. This idea is consistent with the extensive biochemical heterogeneity reported in a panel of T-cell leukemias that were generated by insertional

mutagenesis in WT and *Kras* mutant mice (29). The observed biochemical variability may also be explained by the fact that *Nf1* inactivation, which reduces cellular GAP activity, has less severe biochemical consequences than an oncogenic *Ras* mutation, which perturbs both the intrinsic *Ras* GTPase and confers resistance to GAPs. Signaling in an *Nf1* mutant cell might therefore be more dependent on tissue type and on input from other constituents of the microenvironment.

Although our data have obvious relevance for understanding SMNs that arise in patients with NF1, they also identify *NF1* as a candidate gene in breast cancers, sarcomas, MDS, and other SMNs in the general population. This idea is consistent with emerging data implicating *NF1* in the pathogenesis of sporadic tumors as exemplified by the high incidence of *NF1* mutations in *de novo* glioblastoma multiforme reported by the Cancer Genome Atlas project (30). Beyond *NF1*, our data also raise the possibility that other mutations that deregulate *Ras* signaling may contribute to the development of common SMNs and play a pivotal role in their malignant growth. Along these lines, it is provocative that immunohistochemical analysis revealed elevated levels of pAkt and pS6 in both *Nf1* mutant and control solid tumors *in vivo*. Cancer survivors who develop an SMN often face limited treatment options and are excluded from participation in clinical trials of novel agents. Our data also suggest that pharmacologic inhibition of *Ras* effectors may prove efficacious in managing some SMNs. Finally, the technique that we have developed for delivering CI to mice can be extended to other anatomic sites/tissues and we recently developed a

procedure to administer focal mammary gland irradiation to mice in an effort to model the high incidence of secondary breast cancer in women who are irradiated for Hodgkin's disease (31, 32). The general strategy of accurately modeling high-dose focal human radiation therapy treatment protocols in mice provides a robust new experimental approach for addressing biologic and translational questions in common SMNs.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

The authors thank Vivian Weinberg for advice on statistical analyses, Jonathan Woo for thoughtful discussions of analytical approaches, and the UCSF Genome Core for their advice and assistance with microsatellite analysis. We also thank Tyler Jacks for providing *Nf1* mutant mice.

Grant Support

This study was supported by NIH grants K08CA115476 (to J.L. Nakamura), P01CA00046 and R37CA72614 (to K. Shannon); and by a SCOR award from the Leukemia and Lymphoma Society of America (to S.C. Kogan and K. Shannon). S.C. Kogan is a Scholar of the Leukemia and Lymphoma Society.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received July 26, 2010; revised October 13, 2010; accepted October 17, 2010; published online January 3, 2011.

References

- Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. *Nat Rev Cancer* 2002;2:124–32.
- Meadows AT, Silber J. Delayed consequences of therapy for childhood cancer. *CA Cancer J Clin* 1985;35:271–86.
- Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, et al. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. *Int J Radiat Oncol Biol Phys* 2008;72:24–33.
- Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. *Cell* 2001;104:593–604.
- Dasgupta B, Gutmann DH. Neurofibromatosis 1: closing the GAP between mice and men. *Curr Opin Genet Dev* 2003;13:20–7.
- Boguski M, McCormick F. Proteins regulating *Ras* and its relatives. *Nature* 1993;366:643–53.
- Donovan S, Shannon KM, Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. *BBA Rev Cancer* 2002;1602:23–45.
- Side LE, Shannon KM. The NF1 gene as a tumor suppressor. In: Upashyaya M, Cooper DN, editors. *Neurofibromatosis type 1*, Human Molecular Genetics series. Oxford, UK: Bios Scientific Publishers; (1998), p. 133–52.
- Maris JM, Wiersma SR, Mahgoub N, Thompson P, Geyer RJ, Hurwitz CG, et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. *Cancer* 1997;79:1438–46.
- Sharif S, Ferner R, Birch JM, Gillespie JE, Gattamaneni HR, Baser ME, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. *J Clin Oncol* 2006;24:2570–5.
- Chao RC, Pyzel U, Fridlyand J, Kuo YM, Teel L, Haaga J, et al. Therapy-induced malignant neoplasms in *Nf1* mutant mice. *Cancer Cell* 2005;8:337–48.
- Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in *Nf1*. *Nat Genet* 1994;7:353–61.
- Ozawa T, Faddegon BA, Hu LJ, Bollen AW, Lamborn KR, Deen DF. Response of intracerebral human glioblastoma xenografts to multi-fraction radiation exposures. *Int J Radiat Oncol Biol Phys* 2006;66:263–70.
- Affara NI, Trempus CS, Schanbacher BL, Pei P, Mallery SR, Bauer JA, et al. Activation of Akt and mTOR in CD34+/K15+ keratinocyte stem cells and skin tumors during multi-stage mouse skin carcinogenesis. *Anticancer Res* 2006;26:2805–20.
- Le DT, Kong N, Zhu Y, Lauchle JO, Aiyigari A, Braun BS, et al. Somatic inactivation of *Nf1* in hematopoietic cells results in a progressive myeloproliferative disorder. *Blood* 2004;103:4243–50.
- Mahgoub N, Taylor BR, Le Beau MM, Gratiot M, Carlson KM, Atwater SK, et al. Myeloid malignancies induced by alkylating agents in *Nf1* mice. *Blood* 1999;93:3617–23.
- Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. *Nf1*; *Trp53* mutant mice develop glioblastoma with evidence of strain-specific effects. *Nat Genet* 2000;26:109–13.
- Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, et al. Early inactivation of p53 tumor suppressor gene cooperating with *NF1* loss induces malignant astrocytoma. *Cancer Cell* 2005;8:119–30.
- Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. GammaH2AX and cancer. *Nat Rev Cancer* 2008;8:957–67.

20. Vandenbroucke I, Van Oostveldt P, Coene E, De Paepe A, Messiaen L. Neurofibromin is actively transported to the nucleus. *FEBS Lett* 2004;560:98–102.
21. Basu SK, Schwartz C, Fisher SG, Hudson MM, Tarbell N, Muhs A, et al. Unilateral and bilateral breast cancer in women surviving pediatric Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 2008;72:34–40.
22. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. *J Natl Cancer Inst* 2005;97:1428–37.
23. Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. *JAMA* 1997;278:1262–7.
24. Modan B, Baidatz D, Mart H, Steinitz R, Levin SG. Radiation-induced head and neck tumours. *Lancet* 1974;1:277–9.
25. Neglia JP, Meadows AT, Robison LL, Kim TH, Newton WA, Ruymann FB, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. *N Engl J Med* 1991;325:1330–6.
26. Zhu Y, Harada T, Liu L, Lush ME, Guignard F, Harada C, et al. Inactivation of NF1 in CNS causes increased glial progenitor proliferation and optic glioma formation. *Development* 2005;132:5577–88.
27. Alcantara Llaguno S, Chen J, Kwon CH, Jackson EL, Li Y, Burns DK, et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. *Cancer Cell* 2009;15:45–56.
28. Darby SC, Doll R, Gill SK, Smith PG. Long term mortality after a single treatment course with X-rays in patients treated for ankylosing spondylitis. *Br J Cancer* 1987;55:179–90.
29. Dail M, Li Q, McDaniel A, Wong J, Akagi K, Huang B, et al. Mutant *Ikzf1*, et al. *KrasG12D*, and *Notch1* cooperate in T lineage leukemogenesis and modulate responses to targeted agents. *Proc Natl Acad Sci U S A* 2010;107:5106–11.
30. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008;455:1061–8.
31. Crump M, Hodgson D. Secondary breast cancer in Hodgkin's lymphoma survivors. *J Clin Oncol* 2009;27:4229–31.
32. De Bruin ML, Sparidans J, van't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. *J Clin Oncol* 2009;27:4239–46.